Ruby Kuang
YOU?
Author Swipe
View article: Thulium versus holmium: Which is safer for the removal of entombed stents?
Thulium versus holmium: Which is safer for the removal of entombed stents? Open
Introduction: Removal of entombed ureteral stents can be technically challenging, particularly if the stent were to fragment during removal. The purpose of this study was to compare the therapeutic suitability of the thulium fiber laser (T…
View article: Sulfasalazine Inhibits Inflammation and Fibrogenesis in Pancreas via NF-κB Signaling Pathway in Rats with Oxidative Stress-Induced Pancreatic Injury [Retraction]
Sulfasalazine Inhibits Inflammation and Fibrogenesis in Pancreas via NF-κB Signaling Pathway in Rats with Oxidative Stress-Induced Pancreatic Injury [Retraction] Open
Wang Y, Tian F, Yan M, et al. Drug Des Devel Ther. 2016;10:1743–1751. At the authors request, the Editor and Publisher of Drug Design, Development and Therapy wish to retract the published article. Previous concerns had been raised to the …
View article: MP32-14 CONTINUATION OF ANTIPLATELET AND/OR ANTICOAGULATION IN PATIENTS UNDERGOING REZūM PROSTATE ABLATION
MP32-14 CONTINUATION OF ANTIPLATELET AND/OR ANTICOAGULATION IN PATIENTS UNDERGOING REZūM PROSTATE ABLATION Open
You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology II (MP32)1 Apr 2020MP32-14 CONTINUATION OF ANTIPLATELET AND/OR ANTICOAGULATION IN PATIENTS UNDERGOING REZūM PROSTATE ABLATION Ajay Gopalakrish…
View article: DRES-08. A NOVEL XENOGRAFT MODEL REVEALS A GENE CASCADE AND SERUM BIOMARKER DEFINING A MESENCHYMAL TRANSITION DURING THE EVOLUTION OF GLIOBLASTOMA RESISTANCE TO ANTI-ANGIOGENIC THERAPY
DRES-08. A NOVEL XENOGRAFT MODEL REVEALS A GENE CASCADE AND SERUM BIOMARKER DEFINING A MESENCHYMAL TRANSITION DURING THE EVOLUTION OF GLIOBLASTOMA RESISTANCE TO ANTI-ANGIOGENIC THERAPY Open
INTRODUCTION: Bevacizumab treatment of glioblastoma is limited by transient response and acquired resistance. To study transcriptional changes underlying the evolution of bevacizumab resistance and identify resistance biomarkers, we create…
View article: Improved Survival with Decreased Wait Time to Surgery in Glioblastoma Patients Presenting with Seizure
Improved Survival with Decreased Wait Time to Surgery in Glioblastoma Patients Presenting with Seizure Open
BACKGROUND Preoperative seizure is reported to confer favorable prognosis in glioblastoma patients, but studies to date have not investigated how broadly applicable seizure is as a prognostic factor. OBJECTIVE To investigate if prompter su…
View article: Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy
Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy Open
Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alt…
View article: GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance
GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance Open
Clinical trials revealed limited response duration of glioblastomas to VEGF-neutralizing antibody bevacizumab. Thriving in the devascularized microenvironment occurring after antiangiogenic therapy requires tumor cell adaptation to decreas…
View article: SURG-34. IMPROVED SURVIVAL WITH DECREASED WAIT TIME TO SURGERY IN GLIOBLASTOMA PATIENTS PRESENTING WITH SEIZURE
SURG-34. IMPROVED SURVIVAL WITH DECREASED WAIT TIME TO SURGERY IN GLIOBLASTOMA PATIENTS PRESENTING WITH SEIZURE Open
Preoperative seizure is reported to confer favorable prognosis in glioblastoma patients. We investigated if prompter surgical intervention affects this relationship, focusing on the development of tumor growth and/or additional preoperativ…
View article: TMIC-30. ROLE OF MATRIX METALLOPROTEINASE 9 (MMP9) IN RESISTANCE TO ANTI-ANGIOGENIC THERAPY
TMIC-30. ROLE OF MATRIX METALLOPROTEINASE 9 (MMP9) IN RESISTANCE TO ANTI-ANGIOGENIC THERAPY Open
While bevacizumab initially showed great promise as an anti-angiogenic therapy for glioblastoma, randomized clinical trials showed limited duration of efficacy that fails to impact overall survival. Preclinical studies from our group and o…
View article: TMOD-24. A NOVEL XENOGRAFT MODEL REVEALS A GENE CASCADE DEFINING A MESENCHYMAL TRANSITION DURING THE EVOLUTION OF RESISTANCE TO ANTI-ANGIOGENIC THERAPY
TMOD-24. A NOVEL XENOGRAFT MODEL REVEALS A GENE CASCADE DEFINING A MESENCHYMAL TRANSITION DURING THE EVOLUTION OF RESISTANCE TO ANTI-ANGIOGENIC THERAPY Open
Bevacizumab treatment of glioblastoma is limited by transient response and acquired resistance. To study underlying transcriptional changes, we created a novel multigenerational xenograft model of acquired resistance followed by microarray…
View article: DRES-11. A CROSS-ACTIVATING c-Met/β1 INTEGRIN COMPLEX DRIVES THERAPEUTIC RESISTANCE IN GLIOBLASTOMA
DRES-11. A CROSS-ACTIVATING c-Met/β1 INTEGRIN COMPLEX DRIVES THERAPEUTIC RESISTANCE IN GLIOBLASTOMA Open
Invasive resistance limits anti-angiogenic cancer therapies. While c-Met and β1-integrin are implicated, the mechanism by which they drive resistance remains unclear. We investigated the hypothesis that chemotactic c-Met and haptotactic β1…
View article: SURG-37. MODERN POSTOPERATIVE SEIZURE PROPHYLAXIS WITH LEVETIRACETAM IN OVER 300 NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS
SURG-37. MODERN POSTOPERATIVE SEIZURE PROPHYLAXIS WITH LEVETIRACETAM IN OVER 300 NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS Open
Seizures after glioblastoma surgery have been studied in small cohorts before the use of levetiracetam. We studied postoperative seizure rates temporally in a large modern cohort operated on since widespread levetiracetam availability in 2…